Email ID
Password
Business - Strategy
JOB OF THE WEEK Promote your vacancy here
Total sales at Bayer Schering Pharma (BSP) Asia Pacific grew by a currency-adjusted 13% to €1,043 million in 2009, which the subsidiary said placed it among the top 10 pharma multinationals in the region. Top products by sales during the year ...
Grindeks of Latvia has signed an agreement with the national investment and development agency, under which it will receive funding of Ls2.8 million ($5.4 million) from the European Regional Development Fund to build a new 1,400 m 2 plant for the ...
MiddleBrook Pharmaceuticals ' future looks to be in doubt as it is to cut all of its field sales force and a significant portion of its corporate staff to preserve its cash and resources as it pursues its strategic options. The cuts, which are to ...
Daiichi Sankyo is aiming to boost its group operating profit by almost 90% to ¥180 billion ($1.98 billion) in the fiscal year ending March 31st, 2013, on net sales which are seen reaching ¥1,150 billion, a 20% increase over those forecast for the ...
ThromboGenics ' cash and investments grew to €76.7 million last year after its €42 million private placement in November. The balance will give ThromboGenics "the financial resources to continue to pursue [its] strategy of becoming a strong, ...
 
Hospitals' failure to pay pharmaceutical companies and newly announced price cuts are just some of the challenges facing the sector in Greece, Elizabeth Sukkar, Scrip's world editor, discovers. ...
The pharmaceutical industry has long eyed Turkey as one of its key emerging markets, but recent government action, which could see medicine access delayed by years, is giving it a wake-up call, ...
US agencies are making inroads in the use of comparative effectiveness research to support more robust decision-making. Observational studies are an emerging force in this area and promise to ...
 
Jeff George took over as head of Sandoz, Novartis's generics business, in late 2008. With a big push in emerging markets, a leadership position in biosimilars and an expanded focus on injectables, he ...
Developing relationships with medicine regulators in China and India is just one of the challenges facing Emer Cooke, the international face of the European Medicines Agency (EMA), Scrip's Elizabeth ...
At last year's Bio-Europe Spring conference, Trophos 's CEO Dr Damian Marron told Scrip that the French company had high hopes for its lead product TRO19622 (olesoxime) in amyotrophic lateral ...
 
Just as it appeared that the private investment market was beginning to rebound after last year's drought, the monthly total secured by private companies slumped once more in February, a Scrip ...
Private investments began 2010 in a much more positive fashion than at the start of 2009, but were still down on the strong finish to last year, a Scrip analysis has found. A total of 15 companies ...
Emerging markets are a popular topic at the moment, with pharma firms seeking sales growth outside the mature and slowing markets of the west. There are some companies with a long history of ...
 
Background: The renin-angiotensin-aldosterone system (RAAS) is essential for the regulation of blood pressure and may play a critical role in the pathogenesis of cardiovascular diseases. A strong ...
Increasing research interest in the new and unusual properties of nanotechnology-related pharmaceuticals and medical devices has led to international and national reviews of safety regulation. ...
Background: Introduction of highly active antiretroviral therapy has led to a profound reduction in human immunodeficiency virus (HIV) related mortality; although, the complete eradication of the ...
 
COMPANY/ORGANISATION
CONDITION
GEOGRAPHY
DRUG
© 2010 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36